SAB Biotherapeutics, Inc.
SABS
$2.23
$0.3518.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 377.80K | 1.32M | 1.51M | 2.78M | 2.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 377.80K | 1.32M | 1.51M | 2.78M | 2.60M |
| Cost of Revenue | 29.96M | 30.45M | 27.10M | 23.29M | 20.13M |
| Gross Profit | -29.58M | -29.13M | -25.58M | -20.51M | -17.52M |
| SG&A Expenses | 12.71M | 13.78M | 26.19M | 25.28M | 24.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.67M | 44.23M | 53.29M | 48.57M | 44.67M |
| Operating Income | -42.29M | -42.91M | -51.78M | -45.79M | -42.06M |
| Income Before Tax | -34.28M | -34.11M | -45.57M | -40.32M | -39.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.28 | -34.11 | -45.57 | -40.32 | -39.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.28M | -34.11M | -45.57M | -40.32M | -39.87M |
| EBIT | -42.29M | -42.91M | -51.78M | -45.79M | -42.06M |
| EBITDA | -38.71M | -38.12M | -46.82M | -40.82M | -37.26M |
| EPS Basic | -3.70 | -3.68 | -5.84 | -5.69 | -6.26 |
| Normalized Basic EPS | -2.31 | -2.30 | -3.65 | -3.56 | -3.91 |
| EPS Diluted | -3.70 | -3.68 | -5.84 | -5.69 | -6.26 |
| Normalized Diluted EPS | -2.31 | -2.30 | -3.65 | -3.56 | -3.91 |
| Average Basic Shares Outstanding | 37.10M | 37.05M | 34.52M | 30.50M | 26.29M |
| Average Diluted Shares Outstanding | 37.10M | 37.05M | 34.52M | 30.50M | 26.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |